Abstract 1820P
Background
Cardiovascular (CV) events remain a significant cause of mortality amongst men with advanced and metastatic prostate cancer (PCa). The introduction of novel androgen receptor signalling inhibitors (ARSI) has transformed the treatment landscape of PCa in recent years, however their impact on CV toxicity remains unclear. We aimed to assess the CV effects of ARSI treatment in combination with standard of care (SOC) in advanced and metastatic PCa.
Methods
Systematic search of PubMed, SCOPUS, Web of Science, EMBASE and Clinicaltrials.gov were performed to identify randomized controlled trials (RCTs) comparing the addition of ARSI agents (Enzalutamide, Abiraterone, Apalutamide and Darolutamide) with SOC in treatment of non-metastatic and metastatic PCa, across both hormone-sensitive and castrate resistant settings. Outcomes of interest included: CV events defined by CV event grade (primary outcome), hypertension, acute coronary syndrome (ACS), cardiac dysrhythmia, CV death, cerebrovascular event, and venous thromboembolism (secondary outcomes).
Results
A total of 22 studies (n=22,967) were eligible for inclusion. ARSI therapy increased risk of any grade CV event (RR 1.72, 1.49-2.00, p<0.0001) and grade ≥ 3 CV events (RR 1.98 [1.58-2.48] p<0.0001). ARSI therapy also resulted in an increase in grade ≥ 3 hypertension (RR 2.02 [1.62-2.53] p<0.0001), ACS (RR 2.00 [1.46-2.74] p<0.0001), grade ≥3 cardiac dysrhythmia (RR 1.64 [1.23-2.19] p=0.0007), CV related death (RR 1.88 [1.22-2.89] p=0.004) and cerebrovascular events (RR 1.76[1.33-2.34] p<0.0001) across all PCa settings. Subgroup analysis demonstrated increased risk of all CV events and grade ≥3 across the disease spectrum (RR for all CV events: non-metastatic hormone sensitive PCa 2.20 [1.4-3.47], p<0.0007; metastatic hormone sensitive PCa 1.69 [1.39-2.06], p<0.0001; metastatic castrate resistant PCa 1.53 [1.36-1.71], p<0.0001).
Conclusions
There is compelling evidence indicating a significantly increased risk of all and high-grade CV events in men treated with ARSIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Genitourinary Cancer Research Group, University of Manchester, Manchester, United Kingdom.
Funding
Has not received any funding.
Disclosure
N.W. Clarke: Non-Financial Interests, Institutional, Other, Investigator on PRONOUNCE Trial. All other authors have declared no conflicts of interest.
Resources from the same session
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15